Herantis Pharma Plc announced that data highlighting biomarker response in Herantis' First-in-Man clinical trial of intraputamenal CDNF in Parkinson's disease will be presented at the International Parkinson and Movement Disorder Society annual congress from 17 Sept ­ 22 Sept 2021. The presentation includes results from the completed Phase I First-in-Human clinical study in advanced Parkinson's disease (PD) patients with monthly intraputamenal infusions of recombinant human CDNF (rhCDNF) protein at three (3) study centers in Sweden and Finland. The data includes that the primary endpoint of the Phase I trial showing intraputamenal CDNF is safe and well-tolerated. Additionally, as an Exploratory endpoint, Herantis conducted two proteomics studies to explore potential changes in cerebrospinal fluid (CSF) biomarkers. In the targeted CSF proteomics study: Several CSF biomarkers changed in response to CDNF treatment in a subset of 36% of patients who enrolled to this study. The CSF biomarker changes correlated with improved motor function in several patients and dopamine transporter PET signal. Furthermore, the CSF biomarker profiling indicates that there was a biological response to intraputamenal CDNF treatment in a subset of PD patients that may be associated with modulation of proteostasis, neuroinflammation and synaptic remodeling.